Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Sarcoma, Clear Cell 1Myoepithelioma 1Myelodysplastic Syndromes 1Liposarcoma, Myxoid 1Leukemia, Myelomonocytic, Chronic 1Histiocytoma, Angiomatoid Fibrous 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma, Extraskeletal Myxoid 1

Interventions

Cyclophosphamide 2seclidemstat 1prexasertib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1Zoledronic Acid 1Vinorelbine 1Vincristine 1Topotecan 1Temozolomide 1Ramucirumab 1PM 01183 1Irinotecan 1HhAntag691 1Granulocyte Colony-Stimulating Factor 1Filgrastim 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Desmoplastic Small Round Cell Tumor × seclidemstat × Clear all
NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡